Development of a highly potent anti-HBs monoclonal antibody for HBV and HDV therapy: An improvement with unsettled questions
K Mouzannar, TJ Liang - Journal of Hepatology, 2023 - journal-of-hepatology.eu
Chronic hepatitis B is a global public health problem, and coinfection with hepatitis delta
virus (HDV) worsens disease outcome. Here, we describe a hepatitis B virus (HBV) surface …
virus (HDV) worsens disease outcome. Here, we describe a hepatitis B virus (HBV) surface …
[HTML][HTML] Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice
Background & Aims Chronic hepatitis B is a global public health problem, and coinfection
with hepatitis delta virus (HDV) worsens disease outcome. Here, we describe a hepatitis B …
with hepatitis delta virus (HDV) worsens disease outcome. Here, we describe a hepatitis B …
A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity
W Tan, Y Meng, H Li, Y Chen, S Han, J Zeng, A Huang… - MAbs, 2013 - Taylor & Francis
Treatment of chronic hepatitis B virus (HBV) infection with interferon and viral reverse
transcriptase inhibitor regimens results in poor viral clearance, loss of response, and …
transcriptase inhibitor regimens results in poor viral clearance, loss of response, and …
[HTML][HTML] A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection
R Burm, F Van Houtte, L Verhoye, AA Mesalam… - JHEP Reports, 2023 - Elsevier
Background & Aims Elimination of chronic HBV/HDV infection remains a major global health
challenge. Targeting excessive hepatitis B surface antigen (HBsAg) release may provide an …
challenge. Targeting excessive hepatitis B surface antigen (HBsAg) release may provide an …
A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration
Y Jiang, X Chen, X Ye, C Wen, T Xu, C Yu… - Advanced …, 2024 - Wiley Online Library
Chronic hepatitis B (CHB) remains a major public health concern because of the inefficiency
of currently approved therapies in clearing the hepatitis B surface antigen (HBsAg). Antibody …
of currently approved therapies in clearing the hepatitis B surface antigen (HBsAg). Antibody …
[HTML][HTML] A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy
Y Wang, Y Mei, Z Ao, Y Chen, Y Jiang, X Chen, R Qi… - Antiviral Research, 2022 - Elsevier
Sustainable viral suppression with hepatitis B surface antigen (HBsAg) loss is the new
treatment goal for chronic hepatitis B (CHB). The role of antibodies in therapies for persistent …
treatment goal for chronic hepatitis B (CHB). The role of antibodies in therapies for persistent …
[HTML][HTML] Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections.
AJ Gehring, L Salimzadeh - Antiviral Research, 2024 - Elsevier
With the increasing momentum and success of monoclonal antibody therapy in conventional
medical practices, there is a revived emphasis on the development of monoclonal …
medical practices, there is a revived emphasis on the development of monoclonal …
A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal
C Sureau - Gut, 2016 - gut.bmj.com
Even though current antiviral treatments based on pegylated interferon, or nucleos (t) ide
analogues, in mono or combination therapies, have demonstrated clinical benefit to HBV …
analogues, in mono or combination therapies, have demonstrated clinical benefit to HBV …
[PDF][PDF] Lenvervimab, a monoclonal antibody against HBsAg, can induce sustained HBsAg loss in a chronic hepatitis B mouse model
JH Kim, H Kim, TH Kim, W Kim, J Jung… - Journal of Hepatology, 2019 - academia.edu
Results: JNJ-4964 showed potent anti-HBV activity in AAV/HBV mice treated for 12 weeks.
HBV DNA and HBV surface-antigen (HBsAg) concentrations were undetectable for all …
HBV DNA and HBV surface-antigen (HBsAg) concentrations were undetectable for all …
Recent progress on neutralizing antibodies against hepatitis B virus and its implications
B Hong, Y Wen, T Ying - Infectious Disorders-Drug Targets …, 2019 - ingentaconnect.com
Background: Hepatitis B virus (HBV) infection remains a global health problem. As “cure” for
chronic hepatitis B is of current priority, hepatitis B immunoglobulin (HBIG) has been utilized …
chronic hepatitis B is of current priority, hepatitis B immunoglobulin (HBIG) has been utilized …